ProCE Banner Activity

Testing for Microsatellite Instability in the Era of Immune Checkpoint Inhibitors

Clinical Thought
Should we evaluate microsatellite status in all patients with colorectal cancer, regardless of stage and treatment experience? Read my thoughts on how I approach testing in my practice.

Released: July 11, 2017

Expiration: July 10, 2018

No longer available for credit.

Share

Faculty

John L. Marshall

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by an educational grant from

Bristol Myers Squibb

Faculty Disclosure

Primary Author

John L. Marshall, MD

Associate Professor, Hematology/Oncology
Department of Medicine
Georgetown University Hospital
Washington, DC

John L. Marshall, MD, has disclosed that he has received consulting fees, fees for non-CME/CE services, and funds for research support from Amgen, Caris, Celgene, Genentech, and Taiho.